AGING AND CYP-MEDIATED HERB-DRUG INTERACTIONS

衰老和 CYP 介导的草药-药物相互作用

基本信息

  • 批准号:
    6050796
  • 负责人:
  • 金额:
    $ 7.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-09-30 至 2001-08-31
  • 项目状态:
    已结题

项目摘要

Adverse drug effects stemming from hepatic cytochrome P-450-mediated drug interactions are prevalent in the elderly. With the widespread use of herbal dietary supplements, potential herb-drug interactions are also emerging as a significant medical concern. It has been estimated that nearly 1 in 5 individuals taking prescription medications also take herbal supplements. This translates to more than 15 million adults, including nearly 3 million adults aged 65 years or older, who take prescription medications concurrently with herbal supplements. Furthermore, it has been noted that 70 percent of patients do not reveal their herb use to primary care providers. The risk of potential herb-drug interactions, therefore, is considerable. This is especially so in the elderly who not only receive multiple medications, but often exhibit reduced hepatic drug clearance. Documented herb-drug interactions are increasingly reported in the medical literature, and while a few in vitro studies indicate that the phytochemical components of botanical medicines can modulate hepatic drug metabolizing enzymes (cytochrome P-450s, CYP), no prospective studies into the mechanisms underlying such interactions have been conducted in humans. The hypothesis to be tested in this investigation is that elderly patients are at an increased risk for herb-drug interactions secondary to herb-mediated changes in hepatic CYP enzyme activity. The current proposal will utilize parent/metabolite ratios of phenotypic probe drugs to assess the effect chronic herbal supplementation has on hepatic CYP activity in human volunteers of varying age. The goals of this project are: (1) to determine if chronic usage of dietary supplements containing either garlic, gingko biloba, ginseng, or St. John's wort modulate specific hepatic CYP activities (i.e. CYP1A2, CYP2D6, CYP2E1, and CYP3A4); and (2) whether aging potentiates the risk of CYP-mediated herb-drug interactions.
由肝细胞色素p -450介导的药物相互作用引起的药物不良反应在老年人中很普遍。随着草药膳食补充剂的广泛使用,潜在的草药与药物的相互作用也成为一个重要的医学问题。据估计,近五分之一服用处方药的人也服用草药补充剂。这意味着超过1500万成年人,包括近300万65岁或以上的成年人,同时服用处方药和草药补充剂。此外,已经注意到70%的患者没有向初级保健提供者透露他们的草药使用情况。因此,潜在的草药相互作用的风险是相当大的。这在老年人中尤其如此,他们不仅接受多种药物治疗,而且经常表现出肝脏药物清除率降低。医学文献越来越多地报道草药相互作用,虽然一些体外研究表明植物性药物的植物化学成分可以调节肝脏药物代谢酶(细胞色素p -450, CYP),但尚未对人体进行这种相互作用的机制进行前瞻性研究。本研究要验证的假设是,老年患者继发于草药介导的肝脏CYP酶活性变化的草药-药物相互作用的风险增加。目前的提案将利用表型探针药物的亲本/代谢物比率来评估慢性草药补充剂对不同年龄的人类志愿者肝脏CYP活性的影响。该项目的目标是:(1)确定长期使用含有大蒜、银杏叶、人参或圣约翰草的膳食补充剂是否会调节特定的肝脏CYP活性(即CYP1A2、CYP2D6、CYP2E1和CYP3A4);(2)衰老是否会增加cypp介导的草药相互作用的风险。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bill Gurley其他文献

Bill Gurley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bill Gurley', 18)}}的其他基金

In vitro screening of a unique botanical extract collection for herb-drug interaction (HDI) potential
体外筛选独特的植物提取物集合的草药-药物相互作用 (HDI) 潜力
  • 批准号:
    10226906
  • 财政年份:
    2020
  • 资助金额:
    $ 7.3万
  • 项目类别:
CLINICAL ASSESSMENT OF HERB-DRUG INTERACTION
草药-药物相互作用的临床评估
  • 批准号:
    7377677
  • 财政年份:
    2006
  • 资助金额:
    $ 7.3万
  • 项目类别:
CLINICAL ASSESSMENT OF HERB-DRUG INTERACTION
草药-药物相互作用的临床评估
  • 批准号:
    7203401
  • 财政年份:
    2005
  • 资助金额:
    $ 7.3万
  • 项目类别:
Clinical Assessment of Herb-Drug Interaction
草药-药物相互作用的临床评估
  • 批准号:
    6975620
  • 财政年份:
    2004
  • 资助金额:
    $ 7.3万
  • 项目类别:
Clinical Assessment of Herb-Drug Interactions
草药-药物相互作用的临床评估
  • 批准号:
    6803077
  • 财政年份:
    2003
  • 资助金额:
    $ 7.3万
  • 项目类别:
Clinical Assessment of Herb-Drug Interactions
草药-药物相互作用的临床评估
  • 批准号:
    6617149
  • 财政年份:
    2003
  • 资助金额:
    $ 7.3万
  • 项目类别:
Clinical Assessment of Herb-Drug Interactions
草药-药物相互作用的临床评估
  • 批准号:
    6941693
  • 财政年份:
    2003
  • 资助金额:
    $ 7.3万
  • 项目类别:

相似海外基金

Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
  • 批准号:
    24K18114
  • 财政年份:
    2024
  • 资助金额:
    $ 7.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
  • 批准号:
    10089306
  • 财政年份:
    2024
  • 资助金额:
    $ 7.3万
  • 项目类别:
    Collaborative R&D
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
  • 批准号:
    498288
  • 财政年份:
    2024
  • 资助金额:
    $ 7.3万
  • 项目类别:
    Operating Grants
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
  • 批准号:
    498310
  • 财政年份:
    2024
  • 资助金额:
    $ 7.3万
  • 项目类别:
    Operating Grants
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
  • 批准号:
    23K20339
  • 财政年份:
    2024
  • 资助金额:
    $ 7.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
  • 批准号:
    2740736
  • 财政年份:
    2024
  • 资助金额:
    $ 7.3万
  • 项目类别:
    Studentship
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
  • 批准号:
    2305890
  • 财政年份:
    2024
  • 资助金额:
    $ 7.3万
  • 项目类别:
    Fellowship Award
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
  • 批准号:
    2406592
  • 财政年份:
    2024
  • 资助金额:
    $ 7.3万
  • 项目类别:
    Standard Grant
McGill-MOBILHUB: Mobilization Hub for Knowledge, Education, and Artificial Intelligence/Deep Learning on Brain Health and Cognitive Impairment in Aging.
McGill-MOBILHUB:脑健康和衰老认知障碍的知识、教育和人工智能/深度学习动员中心。
  • 批准号:
    498278
  • 财政年份:
    2024
  • 资助金额:
    $ 7.3万
  • 项目类别:
    Operating Grants
Welfare Enhancing Fiscal and Monetary Policies for Aging Societies
促进老龄化社会福利的财政和货币政策
  • 批准号:
    24K04938
  • 财政年份:
    2024
  • 资助金额:
    $ 7.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了